ASCO 2012

Chicago, IL—Of special significance for patients with multiple myeloma who are not properly responding to current therapies, the novel immunomodulatory drug (IMiD) pomalidomide showed strong activity in phase 2 trials reported at the 2012 ASCO meeting.

Transitioning from intravenous (IV) to subcutaneous (SC) bortezomib improves efficiencies within the clinic and could also provide a more satisfactory experience for patients with multiple myeloma, reported investigators from Emory University School of Medicine, Atlanta, GA, in a new, late-breaking study published by the American Society of Clinical Oncology for its 2012 annual meeting (J Clin Oncol. 2012 [30 suppl]:e18553).

Chicago, IL—The first oral proteasome inhibitor to enter clinical investigation in myeloma is MLN9708. The current data from a phase 1 study presented at the 2012 American Society of Clinical Oncology meeting suggested that MLN9708 encourages disease control and durability of responses in a heavily pretreated population with multiple myeloma.

Chicago, IL—With effective agents for myeloma and far too few randomized trials that have compared them, the optimal treatment for the patient with multiple myeloma is far from clear.

Chicago, IL—“Upfront combinations with carfilzomib are certainly showing attractive response rates,” said Robert Z. Orlowski, MD, Associate Professor, Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, who discussed the results of 3 related studies presented at the ASCO 2012 multiple myeloma oral abstracts session.

Results 1 - 5 of 5
  • American Health & Drug Benefits
  • Lynx CME
  • Value-Based Care in Myeloma
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology